从卵母细胞到活产:我们的生物学效率在提高吗?
该回顾性队列研究纳入2014年1月至2020年12月单学术附属生育诊所的12717例患者、20677个自体体外受精周期,共获取248004个卵母细胞和57268个胚胎。全部胚胎用完者每卵母细胞活产率为2.82%,按年龄从<35岁的11.3%降至>42岁的1.2%;添加PGT-A总体未改善结局,年龄≥38-40岁和41-42岁组每卵母细胞活产率提高,而<35岁和35-37岁组降低。
要点
- 全部胚胎用完者每卵母细胞活产率仅2.82%,随年龄增长而降低。
- PGT-A总体未改善每卵母细胞活产率(添加2.88% vs 未添加2.79%)。
- Poisson回归显示年龄阈值38.5岁,低于此值添加PGT-A降低每卵母细胞活产率。
核心结论
- 尽管辅助生殖技术有临床和科学进展,当前卵巢刺激方案下每卵母细胞活产率仍低,反映尚未克服的生物学屏障。
- 总体添加PGT-A未显示改善结局。
研究设计与样本
- 回顾性队列研究,单学术附属生育诊所,2014年1月至2020年12月自体体外受精周期。
- 共12717例患者符合纳入标准,接受20677次卵母细胞检索,获248004个卵母细胞和57268个胚胎(新鲜和冷冻)。
- 无干预;主要结局为每卵母细胞活产率。
- 对剩余冷冻胚胎者,根据美国辅助生殖技术学会全国报告的活产率数据估算预期活产率。
主要发现
- 全部胚胎用完者每卵母细胞活产率为2.82%,年龄<35岁为11.3%,年龄>42岁为1.2%。
- 按PGT-A使用分层,添加PGT-A者每卵母细胞活产率2.88%,未添加者2.79%。
- 按美国辅助生殖技术学会年龄组分层,35-37岁和38-40岁添加PGT-A者每卵母细胞活产率高于未添加者(P<.05)。
- 剩余冷冻胚胎且添加PGT-A者,预期每卵母细胞活产率为8.34%。
- 年龄<35岁和35-37岁添加PGT-A降低每卵母细胞活产率(P<.001和P=.03),38-40岁和41-42岁添加PGT-A提高每卵母细胞活产率(P=.006和P=.005)。
关键数值与推荐
- 全部胚胎用完者每卵母细胞活产率2.82%。
- 年龄<35岁每卵母细胞活产率11.3%,年龄>42岁1.2%。
- 添加PGT-A者每卵母细胞活产率2.88%,未添加者2.79%。
- 剩余冷冻胚胎且添加PGT-A者预期每卵母细胞活产率8.34%。
- 年龄<35岁和35-37岁添加PGT-A降低每卵母细胞活产率(P<.001和P=.03),38-40岁和41-42岁提高(P=.006和P=.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE(S): The objectives of our study were to investigate the live birth rate (LBR) per oocyte retrieved during in vitro fertilization, in patients who had used all their embryos and to extrapolate the LBR in patients with remaining frozen embryos by calculating the expected LBR from these embryos. DESIGN: A retrospective cohort study. SETTING: A single academically affiliated fertility clinic. PATIENT(S): Autologous in vitro fertilization cycles from January 2014 to December 2020. Data on the number of oocytes retrieved, number of embryos obtained and transferred (at cleavage or blastocyst-stage), use of preimplantation genetic testing for aneuploidy (PGT-A), and number of live births were obtained. The expected LBR was estimated in patients with remaining frozen embryos according to nationally reported Society for Assisted Reproductive Technology LBR data. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Live birth rate per oocyte retrieved. RESULT(S): A total of 12,717 patients met the inclusion criteria and underwent a total of 20,677 oocyte retrievals which yielded a total of 248,004 oocytes and 57,268 embryos (fresh and frozen). In patients who had fully utilized all their embryos the LBR per oocyte was 2.82% (ranging from 11.3% aged <35 years to 1.2% aged >42 years). Stratification of the population based on PGT-A utilization yielded similar results (with PGT-A: 2.88% and without PGT-A: 2.79%). When stratified by the Society for Assisted Reproductive Technology age groups, the addition of PGT-A in patients aged 35-37 and 38-40 years yielded higher LBR per oocyte compared with patients who did not add PGT-A (P<.05). In patients with remaining frozen embryos who had added PGT-A, the projected LBR per oocyte was 8.34%. Use of PGT-A in patients aged <35 and 35-37 years decreased LBR per oocyte (P<.001 and P=.03, respectively) but improved LBR per oocyte in patients aged 38-40 and 41-42 years (P=.006 and P=.005, respectively). Poisson regression analysis demonstrated an age threshold of 38.5, below which PGT-A lowers LBR per oocyte compared with no PGT-A. CONCLUSION(S): Despite clinical and scientific advances in Assisted Reproductive Technology, with the current protocols of ovarian stimulation, the LBR per oocyte remains low reflecting a biological barrier that has yet to be overcome. Overall, the addition of PGT-A did not demonstrate improved outcomes.
引用
- Sabbagh R, Mulligan S, Shah J, et al. From oocytes to a live birth: Are we improving the biological efficiency? Fertil Steril. 2023. PMID: 37678730. doi:10.1016/j.fertnstert.2023.08.972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。